Mapping drug-drug interactions in pharmacokinetic boosting of olaparib
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-025-04858-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Joanneke K Overbeek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands. j.k.overbeek@…. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Cobicistat, Neoplasms. Die Arbeit nennt 13 Literaturangaben. Gefördert von: ZonMw.
Abstract (Originalsprache)
INTRODUCTION: In pharmacokinetic (PK) boosting, an intentional drug-drug interaction (DDI) is used to increase the exposure of another drug. PK boosting of the anticancer drug olaparib with the potent Cytochrome P450 (CYP3A)-inhibitor cobicistat can improve oral bioavailability, tolerability, and affordability. Cancer patients often present with many comedications that can also be affected by CYP3A-inhibitors, which requires thorough assessment of DDIs. This may hamper the feasibility of boosting. Here, we report potential DDIs between cobicistat and comedication in a retrospective cohort of patients treated with olaparib and how these DDIs can be mitigated. METHODS: Patients who received olaparib between April 2017 and February 2024 were included. Comedications at the start of olaparib treatment were screened for potential DDIs with cobicistat if PK boosting would have been initiated in these patients. Relevant DDIs were reviewed by an expert panel of pharmacists and clinical pharmacologists and recommendations for mitigating interventions were formulated. RESULTS: In total, 97 patients were included with a median of six concomitant medications per patient (range 0-13). 59% of patients presented with at least one relevant DDI. With the recommended interventions, 14% of patients had a DDI that required additional monitoring and 1% had a contra-indicated DDI. CONCLUSIONS: DDIs were highly prevalent when PK boosting of olaparib is applied. Nonetheless, nearly all DDIs could be mitigated by an intervention and most interventions could be applied without additional monitoring. PK boosting of olaparib with cobicistat is thus considered feasible with appropriate expertise and resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands. j.k.overbeek@lumc.nl.
- Department of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, PO box 9101, Nijmegen, 6500HB, the Netherlands.
- Department of Medical Oncology, Radboud university medical center, Nijmegen, Netherlands.
Förderung
- ZonMw
Zitieren
APA
Overbeek, J. K., Naoom, S. M. S., Nijboer, L., Bloemendal, H. J., Ottevanger, P. B., van Erp, N. P., Burger, D. M., & Ter Heine, R. (2026). Mapping drug-drug interactions in pharmacokinetic boosting of olaparib. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04858-6
Vancouver
Overbeek JK, Naoom SMS, Nijboer L, Bloemendal HJ, Ottevanger PB, van Erp NP, et al. Mapping drug-drug interactions in pharmacokinetic boosting of olaparib. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-025-04858-6
BibTeX
@article{Overbeek2026,
author = {Overbeek, Joanneke K and Naoom, Sarmad M S and Nijboer, Laura and Bloemendal, Haiko J and Ottevanger, Petronella B and van Erp, Nielka P and Burger, David M and Ter Heine, Rob},
title = {Mapping drug-drug interactions in pharmacokinetic boosting of olaparib},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-025-04858-6}
}
EUVIMED